Opinion: Congress must renew a popular, bipartisan FDA program benefiting sick kids

Taking stock of the drug industry, from the lab to the medicine chest

April 7, 2025 Check out STAT+

Sponsored By

By Ed Silverman Pharmalot Columnist, Senior Writer

Adobe STAT+ | Opinion: BridgeBio CEO: Congress must renew a popular, bipartisan FDA program benefiting sick kids BridgeBio CEO calls on Congress to renew a program that aids rare disease drug development that has saved thousands of lives at no cost to taxpayers. By Neil Kumar STAT+ | A brash biotech VC speaks out on headwinds in the industry, and what the future may hold Omega Funds founder Otello Stampacchia may strike some as impudent or cheeky, but his attitudes toward biotech investing have proven successful. By Allison DeAngelis HIV prevention was making great strides. Then Trump's budget axe fell Layoffs at the CDC gutted branches responsible for a slew of HIV prevention services, imperiling decades of progress. By Jason Mast

More around STAT

Check out more exclusive coverage with a STAT+ subscription Read premium in-depth biotech, pharma, policy, and life science coverage and analysis with all of our STAT+ articles.

---

Enjoying Pharmalot? Tell us about your experience Continue reading the latest health & science news with the STAT app Download on the App Store or get it on Google Play

STAT, 1 Exchange Place, Boston, MA ©2025, All Rights Reserved. I no longer wish to receive STAT emails

Update Newsletter Preferences     •    Contact Us     •    Advertise with Us     •    View in Browser